新型异噻唑酮喹诺酮 ACH-702 对结核分枝杆菌和其他分枝杆菌的体外活性。
In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
机构信息
Servicio de Dermatología, Hospital Universitario José E. González, Monterrey, Nuevo León, México.
出版信息
Antimicrob Agents Chemother. 2010 May;54(5):2188-90. doi: 10.1128/AAC.01603-09. Epub 2010 Mar 15.
Abstract
In this work, we describe the activity of ACH-702 against clinical isolates of Mycobacterium tuberculosis and six different nontuberculous mycobacteria. The MIC(50) and MIC(90) of both susceptible and drug-resistant M. tuberculosis strains tested were 0.0625 and 0.125 microg/ml, respectively. The MIC(50) and MIC(90) values for Mycobacterium fortuitum isolates were 0.0625 microg/ml in both cases; Mycobacterium avium complex isolates showed MIC(50) and MIC(90) values of 0.25 and 4 microg/ml, respectively.
摘要
在这项工作中，我们描述了 ACH-702 对结核分枝杆菌临床分离株和六种不同非结核分枝杆菌的活性。测试的敏感和耐药结核分枝杆菌菌株的 MIC(50)和 MIC(90)分别为 0.0625 和 0.125μg/ml。分枝杆菌弗氏亚种分离株的 MIC(50)和 MIC(90)值均为 0.0625μg/ml；鸟分枝杆菌复合群分离株的 MIC(50)和 MIC(90)值分别为 0.25 和 4μg/ml。
相似文献
1
In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
Antimicrob Agents Chemother. 2010 May;54(5):2188-90. doi: 10.1128/AAC.01603-09. Epub 2010 Mar 15.
2
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Antimicrob Agents Chemother. 2010 Jun;54(6):2684-6. doi: 10.1128/AAC.01545-09. Epub 2010 Apr 5.
3
New antimycobacterial S-alkylisothiosemicarbazones.
Folia Microbiol (Praha). 2005;50(6):479-81. doi: 10.1007/BF02931433.
4
New antimycobacterial 2,3-dihydro-1-alkylindole-2-thiones.
Folia Microbiol (Praha). 2006;51(1):25-6. doi: 10.1007/BF02931445.
5
[Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kekkaku. 2006 Apr;81(4):329-35.
6
Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008.
Chin Med J (Engl). 2010 Jan 20;123(2):184-7.
7
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
Diagn Microbiol Infect Dis. 1992 Feb;15(2):169-71. doi: 10.1016/0732-8893(92)90044-t.
8
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
9
In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.
Antimicrob Agents Chemother. 2006 Dec;50(12):4027-9. doi: 10.1128/AAC.00763-06. Epub 2006 Oct 2.
10
Activities of linezolid against rapidly growing mycobacteria.
Antimicrob Agents Chemother. 2001 Mar;45(3):764-7. doi: 10.1128/AAC.45.3.764-767.2001.
引用本文的文献
1
Advances in antibacterial agents for .
RSC Med Chem. 2024 Oct 18;16(1):37-49. doi: 10.1039/d4md00508b.
2
Looking beyond Typical Treatments for Atypical Mycobacteria.
Antibiotics (Basel). 2020 Jan 3;9(1):18. doi: 10.3390/antibiotics9010018.
3
NTM drug discovery: status, gaps and the way forward.
Drug Discov Today. 2018 Aug;23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001. Epub 2018 Apr 7.
4
Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages.
Ann Clin Microbiol Antimicrob. 2014 Apr 4;13:13. doi: 10.1186/1476-0711-13-13.
5
Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
Bioorg Med Chem Lett. 2011 Aug 1;21(15):4585-8. doi: 10.1016/j.bmcl.2011.05.112. Epub 2011 Jun 6.
6
In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.
Antimicrob Agents Chemother. 2011 Jun;55(6):2860-71. doi: 10.1128/AAC.01666-10. Epub 2011 Apr 4.
本文引用的文献
1
In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Antimicrob Agents Chemother. 2007 Nov;51(11):4071-6. doi: 10.1128/AAC.00410-07. Epub 2007 Aug 20.
2
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. doi: 10.1164/rccm.200604-571ST.
3
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Antimicrob Agents Chemother. 2007 Apr;51(4):1259-67. doi: 10.1128/AAC.01315-06. Epub 2007 Jan 22.
4
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
J Med Chem. 2007 Jan 25;50(2):199-210. doi: 10.1021/jm060844e.
5
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Antimicrob Agents Chemother. 2007 Feb;51(2):576-82. doi: 10.1128/AAC.00414-06. Epub 2006 Dec 4.
6
Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents.
J Med Chem. 2006 Jan 12;49(1):39-42. doi: 10.1021/jm051066d.
7
Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
Bioorg Med Chem Lett. 2006 Mar 1;16(5):1272-6. doi: 10.1016/j.bmcl.2005.11.065. Epub 2005 Dec 7.
8
Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
Bioorg Med Chem Lett. 2006 Mar 1;16(5):1277-81. doi: 10.1016/j.bmcl.2005.11.064. Epub 2005 Dec 7.
9
In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tuberculosis.
Ann Saudi Med. 2005 Sep-Oct;25(5):409-12. doi: 10.5144/0256-4947.2005.409.
10
Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
Antimicrob Agents Chemother. 2004 Dec;48(12):4562-5. doi: 10.1128/AAC.48.12.4562-4565.2004.
Zotero 插件